Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUTFree Report) by 2.5% during the 3rd quarter, Holdings Channel reports. The fund owned 153,249 shares of the company’s stock after buying an additional 3,807 shares during the quarter. Bank of New York Mellon Corp’s holdings in Nautilus Biotechnology were worth $484,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Nautilus Biotechnology during the 3rd quarter worth $71,000. Nuveen Asset Management LLC increased its position in shares of Nautilus Biotechnology by 14.8% during the 2nd quarter. Nuveen Asset Management LLC now owns 191,921 shares of the company’s stock worth $743,000 after purchasing an additional 24,809 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Nautilus Biotechnology during the 2nd quarter worth about $61,000. Wells Fargo & Company MN increased its position in shares of Nautilus Biotechnology by 122.2% during the 2nd quarter. Wells Fargo & Company MN now owns 19,530 shares of the company’s stock worth $76,000 after purchasing an additional 10,739 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Nautilus Biotechnology by 3.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 95,161 shares of the company’s stock worth $368,000 after purchasing an additional 3,396 shares during the last quarter. Hedge funds and other institutional investors own 35.90% of the company’s stock.

Nautilus Biotechnology Trading Up 5.4 %

Shares of NASDAQ:NAUT opened at $2.95 on Tuesday. The business has a 50-day moving average price of $3.01 and a 200 day moving average price of $2.99. The company has a market capitalization of $368.60 million, a price-to-earnings ratio of -6.02 and a beta of 1.20. Nautilus Biotechnology, Inc. has a 12-month low of $1.78 and a 12-month high of $4.65.

Nautilus Biotechnology Company Profile

(Free Report)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Further Reading

Want to see what other hedge funds are holding NAUT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nautilus Biotechnology, Inc. (NASDAQ:NAUTFree Report).

Institutional Ownership by Quarter for Nautilus Biotechnology (NASDAQ:NAUT)

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.